Literature DB >> 16773419

Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir.

Sabiha Hussain1, Abeer Khayat, Asad Tolaymat, Mobeen H Rathore.   

Abstract

Tenofovir-related tubule damage characterized by Fanconi syndrome, renal insufficiency and nephrogenic diabetes insipidus has been reported in the adult HIV-infected population. To our knowledge there has been no reported case of such complications in the pediatric population. We report the case of a 12-year-old perinatally HIV-infected African-American girl who developed nephrogenic diabetes insipidus, renal insufficiency and Fanconi-like syndrome while taking tenofovir (Viread) in combination with lopinavir-ritonavir (Kaletra) and didanosine (Videx).

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16773419     DOI： 10.1007/s00467-006-0109-3

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


  8 in total

1.  Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure.

Authors:  Brian S Rifkin; Mark A Perazella
Journal:  Am J Med       Date:  2004-08-15       Impact factor: 4.965

2.  Tenofovir-related nephrotoxicity in HIV-infected patients.

Authors:  Ana Barrios; Teresa García-Benayas; Juan González-Lahoz; Vincent Soriano
Journal:  AIDS       Date:  2004-04-09       Impact factor: 4.177

3.  Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus.

Authors:  Alexandre Karras; Matthieu Lafaurie; André Furco; Anne Bourgarit; Dominique Droz; Daniel Sereni; Christophe Legendre; Frank Martinez; Jean-Michel Molina
Journal:  Clin Infect Dis       Date:  2003-04-04       Impact factor: 9.079

4.  Dideoxyinosine-associated nephrotoxicity.

Authors:  M A Crowther; W Callaghan; A B Hodsman; I D Mackie
Journal:  AIDS       Date:  1993-01       Impact factor: 4.177

5.  Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine.

Authors:  Florence Rollot; Eve-Marie Nazal; Laurence Chauvelot-Moachon; Charikleia Kélaïdi; Nathalie Daniel; Mona Saba; Sebastien Abad; Philippe Blanche
Journal:  Clin Infect Dis       Date:  2003-11-18       Impact factor: 9.079

6.  Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases.

Authors:  Hélène Peyrière; Jacques Reynes; Isabelle Rouanet; Nathalie Daniel; Corinne Merle de Boever; Jean-Marc Mauboussin; Hélène Leray; Laurence Moachon; Denis Vincent; Dominique Salmon-Céron
Journal:  J Acquir Immune Defic Syndr       Date:  2004-03-01       Impact factor: 3.731

7.  Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity.

Authors:  Steven Coca; Mark A Perazella
Journal:  Am J Med Sci       Date:  2002-12       Impact factor: 2.378

Review 8.  Effect of tenofovir on didanosine absorption in patients with HIV.

Authors:  Patricia Pecora Fulco; Margaret A Kirian
Journal:  Ann Pharmacother       Date:  2003-09       Impact factor: 3.154
  8 in total
  17 in total

1.  Analysis of three-dimensional systems for developing and mature kidneys clarifies the role of OAT1 and OAT3 in antiviral handling.

Authors:  Megha A Nagle; David M Truong; Ankur V Dnyanmote; Sun-Young Ahn; Satish A Eraly; Wei Wu; Sanjay K Nigam
Journal:  J Biol Chem       Date:  2010-10-04       Impact factor: 5.157

2.  Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors.

Authors:  Warren A Andiman; Miriam C Chernoff; Charles Mitchell; Murli Purswani; James Oleske; Paige L Williams; Hans Spiegel; Phil Gona; George R Seage
Journal:  Pediatr Infect Dis J       Date:  2009-07       Impact factor: 2.129

Review 3.  Update on tenofovir toxicity in the kidney.

Authors:  Andrew M Hall
Journal:  Pediatr Nephrol       Date:  2012-08-10       Impact factor: 3.714

Review 4.  Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.

Authors:  Michael N Neely; Natella Y Rakhmanina
Journal:  Clin Pharmacokinet       Date:  2011-03       Impact factor: 6.447

Review 5.  Renal and Bone Adverse Effects of a Tenofovir-Based Regimen in the Treatment of HIV-Infected Children: A Systematic Review.

Authors:  Rose I Okonkwo; Anita E Weidmann; Emmanuel E Effa
Journal:  Drug Saf       Date:  2016-03       Impact factor: 5.606

6.  Tenofovir-Associated Nephrotoxicity in Children with Perinatally-Acquired HIV Infection: A Single-Centre Cohort Study.

Authors:  Yinru Lim; Hermione Lyall; Caroline Foster
Journal:  Clin Drug Investig       Date:  2015-05       Impact factor: 2.859

Review 7.  Kidney disease in HIV-positive children.

Authors:  Mignon I McCulloch; Patricio E Ray
Journal:  Semin Nephrol       Date:  2008-11       Impact factor: 5.299

8.  Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy.

Authors:  Carla E Ransom; Yanling Huo; Kunjal Patel; Gwendolyn B Scott; Heather D Watts; Paige Williams; George K Siberry; Elizabeth G Livingston
Journal:  J Acquir Immune Defic Syndr       Date:  2013-12-01       Impact factor: 3.731

Review 9.  Nucleoside and nucleotide reverse transcriptase inhibitors in children.

Authors:  Carlo Giaquinto; Osvalda Rampon; Martina Penazzato; Federica Fregonese; Anita De Rossi; Ruggiero D'Elia
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

10.  Tenofovir-related Fanconi's syndrome and osteomalacia in a teenager with HIV.

Authors:  Julie M Lucey; Peter Hsu; John B Ziegler
Journal:  BMJ Case Rep       Date:  2013-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.